Kymera Therapeutics, Inc.
KYMR
$24.12
$1.727.68%
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Net Income | -70.75M | -62.49M | -42.06M | -48.56M | -14.37M |
Total Depreciation and Amortization | 1.99M | 1.99M | 1.94M | 1.46M | 891.00K |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 10.53M | 11.28M | 10.32M | 13.82M | 9.63M |
Change in Net Operating Assets | -3.55M | -971.00K | -13.13M | -6.32M | 11.89M |
Cash from Operations | -61.78M | -50.19M | -42.94M | -39.59M | 8.05M |
Capital Expenditure | -936.00K | 189.00K | -4.69M | -7.40M | -11.63M |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | 69.50M | -157.87M | 20.33M | -323.21M | 30.58M |
Cash from Investing | 68.57M | -157.68M | 15.64M | -330.61M | 18.95M |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -293.00K | -641.00K | -352.00K | -290.00K | 925.00K |
Issuance of Common Stock | 31.42M | 251.56M | 1.76M | 354.05M | 1.01M |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -28.36M | -- | -- | -- | -- |
Cash from Financing | 2.77M | 250.92M | 1.41M | 353.76M | 1.93M |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 9.55M | 43.05M | -25.88M | -16.44M | 28.93M |